<unk> , sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In April 2016, the U.S. FDA added a warning about increased risk of heart failure. This was based on data in an article that concluded "DPP-4 inhibition with<unk>  did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although<unk>  improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes."
Saxagliptin
Linagliptin
Sitagliptin
Vildagliptin
Liraglutide
Exenatide
Canagliflozin
Pioglitazone